A mouse model for EML4-ALK-positive lung cancer
- PMID: 19064915
- PMCID: PMC2605003
- DOI: 10.1073/pnas.0805381105
A mouse model for EML4-ALK-positive lung cancer
Abstract
EML4-ALK is a fusion-type protein tyrosine kinase that is generated in human non-small-cell lung cancer (NSCLC) as a result of a recurrent chromosome inversion, inv (2)(p21p23). Although mouse 3T3 fibroblasts expressing human EML4-ALK form transformed foci in culture and s.c. tumors in nude mice, it has remained unclear whether this fusion protein plays an essential role in the carcinogenesis of NSCLC. To address this issue, we have now established transgenic mouse lines that express EML4-ALK specifically in lung alveolar epithelial cells. All of the transgenic mice examined developed hundreds of adenocarcinoma nodules in both lungs within a few weeks after birth, confirming the potent oncogenic activity of the fusion kinase. Although such tumors underwent progressive enlargement in control animals, oral administration of a small-molecule inhibitor of the kinase activity of ALK resulted in their rapid disappearance. Similarly, whereas i.v. injection of 3T3 cells expressing EML4-ALK induced lethal respiratory failure in recipient nude mice, administration of the ALK inhibitor effectively cleared the tumor burden and improved the survival of such animals. These data together reinforce the pivotal role of EML4-ALK in the pathogenesis of NSCLC in humans, and they provide experimental support for the treatment of this intractable cancer with ALK inhibitors.
Conflict of interest statement
Conflict of interest statement: K.T. is a consultant for Dako.
Figures
Similar articles
-
Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.J Thorac Oncol. 2017 Mar;12(3):491-500. doi: 10.1016/j.jtho.2016.10.022. Epub 2016 Nov 9. J Thorac Oncol. 2017. PMID: 27836576
-
Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.Cancer Res. 2008 Jul 1;68(13):4971-6. doi: 10.1158/0008-5472.CAN-07-6158. Cancer Res. 2008. PMID: 18593892
-
Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.Neoplasia. 2011 Jan;13(1):1-11. doi: 10.1593/neo.101120. Neoplasia. 2011. PMID: 21245935 Free PMC article.
-
ALK inhibitors in the treatment of advanced NSCLC.Cancer Treat Rev. 2014 Mar;40(2):300-6. doi: 10.1016/j.ctrv.2013.07.002. Epub 2013 Aug 7. Cancer Treat Rev. 2014. PMID: 23931927 Review.
-
Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.Int J Mol Sci. 2023 Mar 18;24(6):5821. doi: 10.3390/ijms24065821. Int J Mol Sci. 2023. PMID: 36982897 Free PMC article. Review.
Cited by
-
EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.J Exp Med. 2024 Mar 4;221(3):e20232028. doi: 10.1084/jem.20232028. Epub 2024 Jan 29. J Exp Med. 2024. PMID: 38284990
-
Receptor tyrosine kinases: biological functions and anticancer targeted therapy.MedComm (2020). 2023 Dec 7;4(6):e446. doi: 10.1002/mco2.446. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 38077251 Free PMC article. Review.
-
EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis.J Thromb Thrombolysis. 2024 Jan;57(1):67-81. doi: 10.1007/s11239-023-02916-5. Epub 2023 Nov 8. J Thromb Thrombolysis. 2024. PMID: 37940761 Free PMC article.
-
Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.Genes (Basel). 2023 Oct 4;14(10):1906. doi: 10.3390/genes14101906. Genes (Basel). 2023. PMID: 37895255 Free PMC article. Review.
-
Alk-rearranged lung adenocarcinoma: From molecular genetics to therapeutic targeting.Tumori. 2024 Apr;110(2):88-95. doi: 10.1177/03008916231202149. Epub 2023 Sep 29. Tumori. 2024. PMID: 37772924 Free PMC article. Review.
References
-
- Schiller JH, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98. - PubMed
-
- Paez JG, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
-
- Shigematsu H, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–346. - PubMed
-
- Li D, et al. Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007;12:81–93. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases